CTOs on the Move

Syndax

www.syndax.com

 
Syndax is a clinical stage biopharmaceutical company developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer (TNBC). Entinostat is an oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body`s immune response to tumors. Entinostat is being evaluated as a combination therapeutic in Phase 1b/2 clinical trials with Merck and Co., Inc. for non-small cell lung cancer and melanoma, with Genentech, Inc. for TNBC, and with ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.syndax.com
  • 400 Totten Pond Road Suite 110
    Waltham, MA USA 02451
  • Phone: 781.419.1400

Executives

Name Title Contact Details
Madhuli Rembhotkar
 Executive Director ,IT Profile
Sara Parsons
 Senior Director, IT Profile
Tyson Kamikawa
 Vice President Information Technology Profile

Funding

Syndax raised $80M on 08/24/2015
Syndax raised $30M on 01/31/2020

Similar Companies

IDbyDNA

Delivering on our promise to identify any microbe, from any sample, anywhere in the world will take a team of dedicated, passionate, and experienced individuals. The members of our team at IDbyDNA have a strong track record of building successful organizations and bring a breadth of multi-disciplinary experience including; microbial genomics, bioinformatics, software engineering, laboratory medicine, and commercialization. In concert with the global community of researchers, clinicians, industry partners and policy makers, we will revolutionize microbial detection and bring new solutions to solve problems that are not currently addressable with today`s technologies.

Imerjent

Imerjent is a Wilsonville, OR-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ZYTO Corporation

ZYTO Corporation is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Laboratory for Advanced Medicine

The Laboratory for Advanced Medicine, Inc. (LAM) is a bio-pharmaceutical company dedicated to developing revolutionary non-invasive, non-toxic technologies for disease diagnosis and intervention, with an emphasis on cancer.

IsoPlexis

IsoPlexis is leading a new era of functional proteomics. By identifying our most proteomically active single cells (or "superhero cells") for the first time, IsoPlexis enables researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies and at the majority of leading U.S. comprehensive cancer centers.